TABLE 7.

Previous Publications on IPMN Recurrence (Sort by Year)

Authors	Year	Study Type	IPMN Cohort	No. of Cases	Definition of Margin Positivity	Margin Positive	Margin Positivity Risk Factor for Recurrence	Median Follow-Up
White et al14	2007	SC	Noninvasive	78	Any grade of dysplasia; PanIN 3 (only) explicitly included	29.5% (n = 23)	Yes	40 months
Park et al15	2011	SC	Unselected	103	Any grade of dysplasia including invasive carcinoma	4.9% (n = 5)	No	26.7 months
Mariya and Traverso16	2012	SC	Unselected	203	Any grade of dysplasia including invasive carcinoma	6.9% (n = 14)	No	40 months
He et al5	2013	SC	Noninvasive	130	Not explicitly stated	20% (n = 26)	No	38 months
Frankel et al9	2013	SC	Noninvasive	192	Any grade of dysplasia; PanIN explicitly included	45% (n = 86)	Yes	46 months
Kang et al17	2014	SC	Unselected	366	Any grade of dysplasia	17.8% (n = 65)	No	44.4 months
Marchegiani et al6	2015	SC	Unselected	381	Any grade of dysplasia including invasive carcinoma	15.5% (n = 59)	Yes	58 months*
Marchegiani et al18	2015	SC	Main duct	173	High-grade dysplasia or invasive carcinoma only	9.8% (n = 17)	Yes	56 months*
Yamaguchi et al19	2016	SC	Unselected	55	Not explicitly stated	29.1% (n = 16)	No	2.3 years
Dhar et al20	2018	MC (8)	Noninvasive	330	Any grade of dysplasia; PanIN explicity included	19.7% (n = 65)	No	36 months
Al Efishat et al22	2018	SC	Noninvasive +microinvasive (≤10 mm of invasive component)	319	Any grade of dysplasia including invasive carcinoma; PanIN explicitly included	50.8% (n = 162)	No	42 months
Hirono et al21	2020	MC (11)	Unselected	1074	High-grade dysplasia or invasive IPMC; PanIN 3 (only) explicitly included	Not reported	No	54.2 months
Our study	2020	SC	Noninvasive	126	Any grade of dysplasia; PanIN explicitly included	71.4% (n = 90)	No	114 months

MC indicates multicenter (number of institutions); SC, single-center.

^*Follow-up of survivors only.